New drug combo with radiation for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of a new form of chemotherapy (docetaxel albumin-bound), an immunotherapy (SG001), and standard chemotherapy (cisplatin) plus radiation for people with advanced esophageal cancer that cannot be surgically removed. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a type of esophageal cancer called squamous cell carcinoma that is locally advanced and cannot be removed by surgery.
- You have not had any prior treatment for esophageal cancer, like chemotherapy or radiation.
- You are in good enough health to receive chemotherapy and radiation, with no serious heart or lung problems, active infections, or autoimmune diseases.
- You are willing to use effective birth control and not donate sperm or breastfeed during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (cadonilimab) given before surgery for advanced esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests a new immunotherapy drug (camrelizumab) combined with standard chemotherapy and radiation to treat advanced esophageal cancer while avoiding surgery if possible. The goal is to shrink the tumor and help you keep your esophagus working.
This Phase 1/2 trial tests a treatment plan using chemotherapy plus radiation for esophageal squamous cell cancer that cannot be removed with surgery. It may help shrink or control the cancer and guide safer dosing, but it’s only for people with specific tumor stage, health status, and blood test results.
This trial tests a combination of radiation, chemotherapy (cisplatin and paclitaxel), and an immunotherapy drug called camrelizumab for patients with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if adding immunotherapy improves outcomes compared to standard treatment alone.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
Hear when a new Locally Advanced Unresectable Esophageal Squamous Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.